Log in

NASDAQ:CLSN - Celsion Stock Price, Forecast & News

$1.35
+0.01 (+0.75 %)
(As of 02/17/2020 02:59 AM ET)
Add
Today's Range
$1.16
Now: $1.35
$1.36
50-Day Range
$1.34
MA: $1.55
$1.72
52-Week Range
$1.05
Now: $1.35
$2.63
Volume310,938 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:CLSN
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees29
Next Earnings Date4/3/2020 (Estimated)
OptionableOptionable

Receive CLSN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter.


Celsion (NASDAQ:CLSN) Frequently Asked Questions

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

When did Celsion's stock split? How did Celsion's stock split work?

Celsion shares reverse split on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) issued its quarterly earnings data on Friday, November, 15th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.30) by $0.05. The biotechnology company earned $0.13 million during the quarter, compared to the consensus estimate of $0.13 million. View Celsion's Earnings History.

When is Celsion's next earnings date?

Celsion is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Celsion.

What is the consensus analysts' recommendation for Celsion?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celsion.

Has Celsion been receiving favorable news coverage?

Media coverage about CLSN stock has trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Celsion earned a news impact score of 2.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Celsion.

What other stocks do shareholders of Celsion own?

Who are Celsion's key executives?

Celsion's management team includes the folowing people:
  • Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 68)
  • Mr. Jeffrey W. Church CPA, CPA, CFO, Exec. VP & Corp. Sec. (Age 62)
  • Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 59)
  • Dr. Nicholas Borys, Exec. VP & Chief Medical Officer (Age 60)
  • Mr. Timothy J. Tumminello, Chief Accounting Officer & Controller (Age 61)

Who are Celsion's major shareholders?

Celsion's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.35%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper. View Institutional Ownership Trends for Celsion.

Which institutional investors are buying Celsion stock?

CLSN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper. View Insider Buying and Selling for Celsion.

How do I buy shares of Celsion?

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Celsion's stock price today?

One share of CLSN stock can currently be purchased for approximately $1.35.


MarketBeat Community Rating for Celsion (NASDAQ CLSN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  369 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  660
MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote "Outperform" if you believe CLSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Overbought

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel